Veloxis seeks FDA OK for kidney transplant drug Envarsus
This article was originally published in Scrip
Executive Summary
Danish drug maker Veloxis Pharmaceuticals is seeking the FDA's approval to market the firm's once-daily tablet version of tacrolimus under the brand name Envarsus (LCP-Tacro) as a therapy to prevent organ rejection in kidney transplant recipients.